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Risk of invasive fungal infection in patients affected by acute
promyelocytic leukaemia. A report by the SEIFEM-D registry
Patients with acute promyelocytic leukaemia (APL) are usu-
ally considered at lower risk for developing an infectious
complication (Girmenia et al, 2003), principally because cur-
rent treatments are mainly based on the induction of mye-
loid differentiation rather than the highly myeloablative
properties of standard chemotherapy used in patients with
acute myeloid leukaemia (AML).
This prospective study, conducted in 33 locations
throughout Italy, evaluated the incidence of invasive fungal
infection (IFI) and the clinical characteristics in patients with
APL compared to patients affected by other AML subtypes
treated with intensive chemotherapy. Consecutive adult
patients with newly diagnosed AML (n = 1192) were enrolled
in the study between 1 January, 2010 and 30 April, 2012:
1086 had non promyelocytic-AML (npAML) and 106 had
APL.
Only 881 of the 1086 npAML patients received intensive
chemotherapy and were considered evaluable. Two-hundred
and fourteen cases of IFIs were recorded (24%) after the
induction phase, with 23 yeast infections (3%) and 191
moulds (22%). The majority of moulds were possible (136,
71%), while the remaining 55 cases were probable (n = 48)
or proven (n = 7) IFIs (Table I). Three of the 106 APL
patients were excluded from the analysis (one early haemor-
rhagic death and two poor performance status). Among the
remaining 103 patients, 90 were treated with all trans retinoic
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acid (ATRA) plus chemotherapy including idarubicin and 13
received ATRA plus arsenic trioxide (ATO).
Overall, 10 APL patients (97%) had an IFI: eight in induc-
tion phase, one in consolidation and one at time of relapse. All
eight patients (77%) who developed an IFI after induction
treatment (one proven, three probable and four possible) had a
mould infection. All IFIs were observed in patients treated with
ATRA plus chemotherapy. Overall, eight APL patients died
during the induction phase (one IFI, four cerebral haemorrhage
and three bacterial sepsis). A total of 95 patients (92%) achieved
a complete remission (CR). All APL patients were further fol-
lowed for a median duration of 36 months (range 3–54) and
only two more cases of IFI have been observed: one possible
mould infection during consolidation (mitoxantrone, etoposide
and ATRA) at 16 weeks from APL diagnosis, and one probable
case in a patient with relapsed APL at 132 weeks. Notably, six
of the 95 patients (6%) who achieved CR subsequently relapsed.
Among these patients, only four received a second induction
treatment, two with ATO + ATRA and two with standard
AML-like chemotherapy. One probable pulmonary aspergillosis
was reported in a patient who had received a fludarabine-based
chemotherapy (Table II). Only one patient died of cerebral
aspergillosis during first induction, while the remaining seven
patients were successfully treated with antifungal therapy. The
patient who developed IFI during consolidation recovered from
infection.
During the follow-up, five additional patients died of sep-
ticaemia (n = 1), cardiac failure (n = 1) and haemorrhage
(n = 3).
Although not completely comparable, the npAML and APL
cohorts were evaluated in order to analyse the main differ-
ences between the two groups within 90 d of starting their
Table I. Main characteristics of APL and AML patients treated with curative chemotherapy and comparison of these two groups of patients for
IFI risk during first induction chemotherapy.
APL (cases) AML (cases) P-value*
Patients (n) 103 881
Age, years, median (IQR) 50 (40–64) 58 (47–66) 001
Male/Female 50/53 448/433 05
Performance status (WHO)
0–1 76 284 <00001
>1 27 597
Mucosal barrier disruption 56 (54%) 512 (58%) 04
Central venous catheter 52 (50%) 687 (78%) <00001
Neutropenia (<1 neutrophils 9 109/l) 103 (100%) 874 (99%) 03
Duration of neutropenia <1 neutrophils 9 109/l, days,
median (IQR)
235 (15–30) 23 (18–29) 045
Duration of severe neutropenia <05 neutrophils 9 109/l, days,
median (IQR)
18 (6–25) 20 (15–26) 0003
Antifungal prophylaxis 94 (91%) 837 (95%) 01
Topical antifungal prophylaxis only 17 (17%) 60 (7%) 00005
Prophylactic used
Fluconazole 33 (32%) 168 (19%) 0002
Itraconazole 13 (12%) 117 (13%) 08
Posaconazole 38 (37%) 513 (58%) <00001
Other 1 (1%) 23 (3%)
IFI
All cases 8 (7%) 214 (24%) 00001
Proven/probable 4 (4%) 77 (9%) 008
Moulds
All cases 8 (7%) 191 (22%) 00006
Proven/probable 4 (4%) 55 (6%) 04
Yeasts
All cases 0 23 (3%) <00001
Antifungal treatment 11 (11%) 275 (31%) <00001
Duration of treatment, days, median (IQR) 14 (7–30) 12 (8–16) 06
Overall mortality at 30 d 8 (8%) 110 (12%) 01
Mortality due to IFI at 30 d 1 (1%) 25 (3%) 05
APL, acute promyelocytic leukaemia; AML, acute myeloid leukaemia; IQR, interquartile range; WHO, World Health Organization; IFI, invasive
fungal infection.
*The Wilcoxon rank sum test was used to compare continuous variables. Categorical variables were evaluated with the v2 or two-tailed Fisher’s
exact test.
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first treatment for leukaemia (Table I). Significant differences
were observed regarding the prophylactic drug used: posaco-
nazole was more frequently applied in npAML. Although the
prophylaxis was less mould-oriented in APL, the overall inci-
dence of IFI and the incidence of mould infections were both
markedly higher in npAML. A significant difference was
observed between APL and npAML with regard to systemic
antifungal treatment, as it was more frequently utilized in
npAML. Interestingly, while the number of patients who
developed neutropenia was similar in the two groups, the
median duration of severe neutropenia (<05 neutrophils
9 109/l) was significantly shorter in the APL arm. No signifi-
cant difference regarding overall mortality and attributable
mortality among the two patient cohorts was recorded. No
significant factors associated with the onset of an IFI among
APL were identified.
Before the advent of ATRA, patients were treated with
chemotherapy alone, which yielded CR rates of 50–80%.
However, deaths were often caused by infections owing to
the use of chemotherapy regimens similar to those adminis-
tered to npAML patients, leading to prolonged severe neu-
tropenia (Cordonnier et al, 1985; Tallman et al, 1997). The
inclusion of ATRA in combination with chemotherapy and
subsequently that of ATO definitely improved patient out-
comes thus turning APL into a highly curable disease. Mean-
while, the use of these agents enabled a decrease/de-
escalation of the chemotherapeutic agents used. The reduc-
tion of the chemotherapeutic ‘burden’ also reduced chemo-
therapy-related toxicity; in particular, the reduced duration
of severe neutropenia observed may, in turn, affect morbidity
and mortality from infectious complications. However the
risk of infection is not completely absent, especially if high
dose cytarabine is included in the consolidation regimen
(Lo-Coco et al, 2010; Sanz et al, 2010; Iland et al, 2012).
Few IFIs in APL have been reported in clinical trials (de la
Serna et al, 2008; Iland et al, 2012), and only four cases
(45%) of non-fatal IFI were reported (one pulmonary myce-
toma, two hepatosplenic candidiasis and one candidaemia)
in a series of 89 APL patients treated with the AIDA protocol
(ATRA + idarubicin) (Girmenia et al, 2003), while in a pae-
diatric series of 33 APL, only two patients (61%) experi-
enced fungal infection (Cellot et al, 2013).
Similar to the results reported in npAML patients (Pagano
et al, 2006), the majority of APL cases in the present study
developed IFI after first induction treatment. All IFIs occurred
in patients treated with ATRA plus chemotherapy. Only a few
patients relapsed and it is noteworthy that one of the two
patients treated with an aggressive second line induction ther-
apy developed an IFI. This suggests that if the patients
had received an aggressive chemotherapy, characterized by a
prolonged neutropenia, the risk of IFI would probably have
been similar to that of npAML.
Overall, the rate of IFI was significantly lower among
patients with APL compared to those with npAML. Unlike the
npAML cohort, posaconazole was significantly less utilized in
APL patients. Another interesting observation is the total
absence of yeast infections in the APL group in our series.
On the basis of this study, APL patients must be consid-
ered at lower risk of IFI if treated with differentiation-induc-
ing agents. Taking the substantial cost of prophylactic
antifungal treatment and the possible side effects, interaction
between azoles and drugs active for the treatment of APL
(Naito et al, 2006) into account, a mould active antifungal
prophylaxis could be omitted in APL patients at the first
induction phase of their treatment.
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